Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 40, Issue 5-6, 2001, Pages 565-579

  Wirt, D P ^a   Giles, F J ^a   Oken, M M ^a   Solal Celigny, P ^a   Robert Beck, J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cost effectiveness; Follicular; Interferon alfa 2b; Lymphoma non Hodgkin's; Meta analysis

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; TENIPOSIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG TOXICITY; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 0035044272     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097655     Document Type: Article

References (48)

1. Management of the low-grade non-Hodgkin's lymphomas
2. National cancer institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
3. Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy
4. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
5. Long-term results of treatment of patients with follicular lymphomas
6. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
7. Lymphosarcoma: A review of 1269 cases
8. Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases
9. Nodular non-Hodgkin's lymphoma (NHL): Factors influencing prognosis and indications for aggressive treatment
10. Malignant lymphomas of follicular center cell origin in man. III. Prognostic features
11. Malignant lymphoma. II. Prognostic factors and response to treatment of 473 patients at the national cancer institute
12. Prognostic value of serum β-2 microglobulin in low-grade lymphoma
13. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma
14. Follicular lymphoma: Prognostic factors for response and survival
15. Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years
16. Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients
17. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model
18. Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle lymphoma group therapy working party
19. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma
20. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades
21. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma
22. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial
23. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires
24. Markov models in medical decision making: A practical guide
25. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method
26. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B
27. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer
28. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer
29. Quality of life in clinical trials of adjuvant therapies
30. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival
31. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making
32. Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia
33. Cost-effectiveness of interferon-alpha as maintenance therapy in chronic myelogenous leukemia
34. Interferon-alpha 2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress
35. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma
36. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up
37. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: A preliminary report of an intergroup trial (CALGB 8691 and EST 7486) [Abstract #1240]
38. Management of follicular lymphoma
39. α Interferon in non-Hodgkins lymphoma - An update of the ECOG I-COPA trial (E6484) [Abstract #2004]
40. A meta-analysis (MA) of randomised trials evaluating the role of interferon (IFN) as treatment for follicular lymphoma (FL) [Abstract #11]
41. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis
42. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia
43. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results
44. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women
45. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C
46. Cost effectiveness of colorectal cancer screening in the elderly
47. Cost effectiveness of vaccination against pneumococcal pneumonia: An update
48. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989